Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway

Biochim Biophys Acta. 2016 Nov;1863(11):2784-2794. doi: 10.1016/j.bbamcr.2016.08.013. Epub 2016 Aug 24.

Abstract

Interleukin-17A, a pro-inflammatory cytokine, has a direct proapoptotic effect on cardiomyocytes. However, the specific mechanism has not been clarified. In the present study, an in-vitro model of cardiomyocyte apoptosis induced by IL-17A stimulation was employed and the roles of iNOS and Stat3 involved were investigated. Our data showed that the neonatal mouse cardiomyocytes express IL-17 receptors: IL-17RA and IL-17RC, but did not express IL-17A. Exogenous IL-17A significantly induces iNOS expression and hence the cardiomyocyte apoptosis. Moreover, IL-17A-induced cardiomyocyte apoptosis can be achieved directly via iNOS activation. We further showed that exogenous IL-17A simultaneously triggers Stat3 activation, which in turn inhibits IL-17A-induced iNOS expression in cardiomyocytes. And both ChIP and dual-luciferase results confirmed that Stat3 directly inhibits transcriptional activities of iNOS via binding to its specific promoter region. Consistent with these data, silencing of Stat3 in fact can aggravate IL-17A-triggered cardiomyocyte apoptosis. Finally, using an in vivo myocardial ischemia/reperfusion injury model, we verified that Stat3 inhibition increased iNOS expression and exacerbated cardiomyocyte apoptosis. Thus, our data strongly support the notion that Stat3 plays a compensatory anti-apoptotic role in IL-17A/iNOS-mediated cardiomyocyte apoptosis via inhibiting iNOS transcription, providing a novel molecular mechanism of apoptosis regulation and complicated interactions between IL-17A/iNOS and IL-17A/Stat3 signalings.

Keywords: Apoptosis; Cardiomyocyte; Interleukin-17A; Ischemia/reperfusion injury; Stat3; iNOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis* / drug effects
  • Binding Sites
  • Cells, Cultured
  • Disease Models, Animal
  • Interleukin-17 / metabolism*
  • Interleukin-17 / pharmacology
  • Male
  • Mice, Inbred C57BL
  • Myocardial Infarction / enzymology*
  • Myocardial Infarction / genetics
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion Injury / enzymology*
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / pathology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / enzymology*
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism*
  • Phosphorylation
  • Promoter Regions, Genetic
  • Receptors, Interleukin-17 / metabolism
  • STAT3 Transcription Factor / antagonists & inhibitors
  • STAT3 Transcription Factor / genetics
  • STAT3 Transcription Factor / metabolism*
  • Signal Transduction
  • Time Factors
  • Transfection
  • Tyrphostins / pharmacology

Substances

  • Il17a protein, mouse
  • Interleukin-17
  • Receptors, Interleukin-17
  • STAT3 Transcription Factor
  • Stat3 protein, mouse
  • Tyrphostins
  • alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse